# Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

> **NCT04763616** · PHASE2 · COMPLETED · sponsor: **Won Seog Kim** · enrollment: 37 (actual)

## Conditions studied

- Natural Killer/T-cell Lymphoma
- Relapsed Natural Killer/T-cell Lymphoma
- Refractory Natural Killer/T-cell Lymphoma

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT04763616
- **Lead sponsor:** Won Seog Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-25
- **Primary completion:** 2023-04-30
- **Final completion:** 2026-04-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04763616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04763616, "Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04763616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*